1,304 patents currently held
52 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
110
Ending by 2030
Dec 2026
Next term end
604
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2031 · High confidence
Also notable
Ends Jun 2027 · High confidence
Also notable
Ends Jan 2032 · High confidence
Also notable
Ends Jul 2031 · High confidence
Also notable
Ends no later than Dec 2031 · Medium confidence
Also notable
Ends Feb 2032 · High confidence
Also notable
Ends Dec 2029 · High confidence
Also notable
Ends Aug 2036 · High confidence
Common Light Chain Mouse
US 10,143,186
Cited by 174 later US patents, top 1% of utility patents granted in 2018 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
VEGF Antagonist Formulations Suitable for Intravitreal Administration
US 11,066,458
Cited by 59 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Human Lambda Light Chain Mice
US 9,012,717
Cited by 129 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
US 8,586,713
The most cited patent in this portfolio, cited by 457 later US patents, top 1% of utility patents granted in 2013 in our data. Protection runs to 2031.
High Affinity Antibodies to Human IL-6 Receptor
US 7,582,298
Cited by 183 later US patents, top 5% of utility patents granted in 2009 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Adam6 Mice
US 8,642,835
Cited by 144 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
High Affinity Human Antibodies to PCSK9
US 8,062,640
Cited by 241 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Taurine Supplemented Cell Culture Medium and Methods of Use
US 11,312,936
Cited by 40 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 11 to 25, 2026 · next Dec 11
- 19 fees due Jan 4 to 28, 2027 · next Jan 4
- 26 fees due Feb 1 to 28, 2027 · next Feb 1
- 23 fees due Mar 1 to 26, 2027 · next Mar 1
- 32 fees due Apr 1 to 30, 2027 · next Apr 1
- 23 fees due May 3 to 28, 2027 · next May 3
- 27 fees due Jun 3 to 30, 2027 · next Jun 3
- 25 fees due Jul 5 to 30, 2027 · next Jul 5
- 24 fees due Aug 4 to 27, 2027 · next Aug 4
- 18 fees due Sep 1 to 26, 2027 · next Sep 1
- 32 fees due Oct 2 to 30, 2027 · next Oct 2
- 9 fees due Nov 5 to 14, 2027 · next Nov 5
Recent changes
- Nov 16Assignment recorded on 1 record: Wu, Jiaxi and 7 others to Regeneron Pharmaceuticals, Inc. Recorded Nov 16, 2026, executed Nov 9, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76763, frame 885.
- Nov 16Assignment recorded on 1 record: Jorgenson, Eric and 5 others to Regeneron Pharmaceuticals, Inc. Recorded Nov 16, 2026, executed Oct 21, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76773, frame 100.
- 44 of the patents on this record were granted since Aug 23, 2026
- 4 terms have ended since Aug 23, 2026
- Nov 11 US 7,521,211 Igf-I and IGF-2 Chimeric Polypeptides and Therapeutic Uses Thereof · term ended
- Oct 28 US 8,871,996 Mice Expressing Human Voltage-Gated Sodium Channels · lapsed on the fee record
- Sep 17 US 7,354,581 Therapeutic Combination of a VEGF Antagonist and Anti-Hypertensive Agent · term ended
- Aug 30 US 11,428,695 Concentration-Dependent Self-Interaction Assay · lapsed on the fee record
What they patent
The largest of its 604 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders | 13 in force | to May 2032 |
| Human Lambda Light Chain Mice | 13 in force | to Jan 2032 |
| VEGF Antagonist Formulations Suitable for Intravitreal Administration | 12 in force | to Jul 2027 |
| Anti-VEGF Protein Compositions and Methods for Producing the Same (2020) | 11 in force | to Aug 2040 |
| Adam6 Mice | 11 in force | to Apr 2032 |
| Humanized Fc gamma R Mice | 10 in force | to Jan 2032 |
| High Affinity Antibodies to Human IL-6 Receptor | 10 in force | to Dec 2031 |
| Non-Human Animals Having a Humanized Signal-Regulatory Protein Gene | 9 in force | to Aug 2036 |
| Humanized IL-6 and IL-6 Receptor | 9 in force | to Oct 2032 |
| Human Antibodies to the Human Glucagon Receptor and Methods of Use Thereof | 9 in force | to Nov 2031 |
| High Affinity Human Antibodies to Human IL-4 Receptor | 9 in force | to Mar 2031 |
| High Affinity Human Antibodies to Human Nerve Growth Factor | 9 in force | to Jul 2029 |
| Anti-VEGF Protein Compositions and Methods for Producing the Same (2020) | 8 in force | to Aug 2040 |
| Production Cell Line Enhancers | 8 in force | to Oct 2033 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,531,172 | Methods of Treating Diseases with a VEGF Antagonist In force · High confidence | In force | High confidence | |
| US 7,732,167 | Interferon-Alpha/Beta Binding Fusion Proteins and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 7,608,430 | Interferon-Gamma Antagonists and Therapeutic Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,080,248 | Method of Treating Rheumatoid Arthritis with an IL-6R Antibody In force · High confidence | In force | High confidence | |
| US 8,183,014 | High Affinity Antibodies to Human IL-6 Receptor In force · High confidence | In force | High confidence | |
| US 8,192,741 | Method of Treating Rheumatoid Arthritis with an ANTI-IL-6R Antibody In force · High confidence | In force | High confidence | |
| US 8,568,721 | Method of Treating Rheumatoid Arthritis with an Anti-IL-6R Antibody In force · High confidence | In force | High confidence | |
| US 9,308,256 | Method of Treating Rheumatoid Arthritis With An Anti-IL-6R Antibody In force · Medium confidence | In force | Medium confidence | |
| US 9,884,916 | High Affinity Antibodies to Human IL-6 Receptor In force · Medium confidence | In force | Medium confidence | |
| US 10,584,173 | Nucleic Acids Encoding High Affinity Antibodies to Human IL-6 Receptor In force · High confidence | In force | High confidence |
Also on record, not counted in the 1,304: 52 patents in force now held by others · 151 patents ended · 861 applications pending · 437 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.